Loading patent…
OwnerScott Strome, Daniel Schindler +3inventors
InventorsScott Strome, Daniel Schindler, Lieping Chen, Harry Meade, Yann Echelard
Estimating the term…
The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
An antibody composition useful for radioimmunotherapy comprising an agonistic 41-BB recombinant antibody, a radionuclide marker molecule and a conjugated toxin.
An antibody composition useful for immunotherapy comprising an agonistic 41-BB recombinant antibody and a conjugated toxin.
A method of radiolabeling an agonistic recombinant 41-BB antibody comprising contacting a conjugate of a 41-BB antibody with a radiometal action that binds sulfhydryl groups, wherein said protein conjugate comprises a chelating agent covalently linked to said 41-BB antibody.
A method of radioimmunoimaging a tumor or an infectious lesion, wherein an agonistic recombinant 41-BB antibody that specifically binds to a target receptor or antigen produced by or associated with said tumor or infectious lesion, and radiolabeled with a radionuclide is parenterally injected into a human patient and, after localization of the radiolabeled antibody can and clearance of the non-target background to clear, the site or sites of accretion of the radiolabeled protein are detected by an external imaging camera or other imaging sensor.
Dependencies are inferred from the claim text.